Experiment 635748

Compounds isolated

Details

PropertyValue
Pharmacology
Administration routeIV
OrganismEmpty organism
CitationWEITMAN,S: LANGEVIN,AM: BERKOW,RL: THOMAS,PJ: HURWITZ,CA: KRAFT,AS: DUBOWY,RL: SMITH,DL: BERNSTEIN,M:. (1999). A PHASE I TRAIL OF BRYOSTATIN-1 IN CHILDREN WITH REFRACTORY SOLID TUMORS: A PEDIATRIC ONCOLOGY GROUP STUDY.. 5(9)
Amount utilized
Compound isolated
DiseaseTWENTY-TWO PATIENTS ON FIVE DOSE LEVELS WERE EVALUABLE FOR TOXICIITES. AT THE 57 MCG/M2/DOSE LEVEL DOSE-LIMITING MYALGIA (GRAD 3) WAS OBSERVED IN THREE PATIENTS; TWO OF THOSE PATIENTS ALSO EXPERIENCED PHOTOPHOBIA OR EYE PAIN, AND ONE EXPERIENCED HEADACHE. SYMPTOMS OCCURRED IN ALL PATIENTS WITHIN 24-72 HRS AFTER THE SECOND DOSE OF BRYOSTATIN-1 WITH RESOLUTION WITHIN 1 WEEK OF ONSET. OTHER OBSERVED TOXICITIES (GRADES 1 AND 2) INCLUCED ELEVATION IN LIVER TRANSAMINASES, THROMBOCYTOPENIA, FEVER, AND FLU-LIKE SYMPTOMS THE BRYOSTATIN-1 INFUSION WAS TYPICALLY WELL TOLERATED. ALTHOUGH STABLE DISEASE WAS NOTED IN SEVERAL PATIENTS, ONLY COMPLETED OR PARTIAL RESPONSES WERE OBSERVED.
Dose amount57.0 MCG
Number2
Qualitative resultACTIVE
AnimalHUMAN CHILD
Per unitSQ M BODY SURFACE
Dose expressionDOSE
GenderGIVEN TO BOTH SEXES